Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth. Read more to see why I rate TGTX stock a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback